心脉医疗收盘上涨3.41%，滚动市盈率31.25倍，总市值139.83亿元

Core Viewpoint - The company, Xinmai Medical, has shown a slight increase in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential investment opportunities despite recent declines in revenue and profit [1][2]. Company Overview - Xinmai Medical specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including aortic stent graft systems and balloon catheters [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - For Q1 2025, Xinmai Medical reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% from the previous year, with a gross margin of 69.61% [2]. Market Position - As of the latest data, Xinmai Medical's PE ratio stands at 31.25, while the industry average is 54.32, indicating that the company is undervalued relative to its peers [3]. - The total market capitalization of Xinmai Medical is approximately 13.983 billion yuan [1][3].